严重急性呼吸道综合征冠状病毒疫苗研究现状  

Current Research on SARS Coronavirus Vaccine

作　　者：叶迅[1] 孟夏[1] 董继斌[2] 梁旻[3] 胡放 陈红专[1] 

机构地区：[1]上海第二医科大学药理学教研室,上海200025 [2]复旦大学药学院生物化学教研室,上海200032 [3]上海三维生物技术有限公司

出　　处：《生物化学与生物物理进展》2003年第3期331-334,共4页Progress In Biochemistry and Biophysics

摘　　要：冠状病毒被认为是新近爆发的严重急性呼吸道综合征的病原体 .迄今公共数据库中已发表了不同国家和地区分离的 12个SARS病毒株基因组完整序列 .突起蛋白是冠状病毒的主要抗原 ,包含许多抗原决定簇 .SARS冠状病毒突起蛋白的相对保守性为有效疫苗的开发奠定了很好的研究基础 .灭活或减毒的冠状病毒疫苗存在一定的局限性和危险性 .A novel coronavirus has been identified to be associated with the newly outbreak of severe acute respiratory syndrome (SARS). To date 12 whole genome sequences from various samples are available in public-domain database. Spike protein of coronavirus is considered to be the major antigen and contains many potential antigenicity domains. The relatively tow mutation rate in spike protein provides high opportunity for effective vaccine development. Since inactivated or attenuated coronavirus holds some potential limitations and risks to prepare and to inoculate, the current best hope for protection is to combine a protein vaccine (i.e., a purified SARS coronavirus spike protein) with a 'vectored' vaccine, consisting of a plasmid or a harmless virus, such as recombinant adenovirus which has been genetically engineered to produce coronavirus spike protein.

关 键 词：严重急性呼吸道综合征 冠状病毒 疫苗 突起蛋白 SARS 基因组 

分 类 号：R373.1[医药卫生—病原生物学] R563.19[医药卫生—基础医学]